The further development of proximity-based platforms will significantly influence the identification of cancer drugs. Proximity-based platforms rely on the principle that molecules or molecular entities, such as proteins or nucleic acids in close physical proximity within a cellular or tissue environment, can interact or affect each other's function, even without direct binding. For example, building upon Shokat's research on KRASG12C using proximity-based platforms, the use of chemoproteomic methods, specifically activitybased protein profiling, has emerged as a practical approach for identifying covalent ligands and potential binding sites for proteins that are difficult to target using traditional drug-discovery methods ( ). Also, Nomura and colleagues recently performed a cysteine-reactive covalent ligand screen to discover chemicals that can interfere with the binding of MYC to its DNA consensus sequence ( . On this screen, EN4 was found as a covalent ligand that specifically targets Cys-171 of MYC within a predicted intrinsically disordered area. Subsequently, this molecule was further refined to establish the first structure-activity relationships. The potential exists for ligandable pockets in numerous traditionally 'undruggable' targets to be discovered by employing mass spectrometry techniques for covalent screening, particularly within the natural cellular environment. This approach could also enable the targeting of intrinsically disordered regions of proteins, which are commonly found in transcription factors ). Discovered by Ebert's team, BI-3802 and CR8 both represent small molecule degraders aiming against BCL6 and CDK, respectively. These compounds enhance already existing protein-protein interactions, hence promoting breakdown. The classic molecular glue, cyclosporin, hooks cyclophilin to block calcineurin, hence modulating IL2 synthesis. Companies such as Revolution Medicines and WarpDrive Bio apply similar ideas for new therapies like KRASG12C inhibitors. By extending the range of druggable targets, these strategies should transform drug development ( ).